Redhill Biopharma Ltd (RDHL) - Total Liabilities

Latest as of March 2026: $21.08 Million USD

Based on the latest financial reports, Redhill Biopharma Ltd (RDHL) has total liabilities worth $21.08 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Redhill Biopharma Ltd - Total Liabilities Trend (2010–2025)

This chart illustrates how Redhill Biopharma Ltd's total liabilities have evolved over time, based on quarterly financial data. See RDHL working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Redhill Biopharma Ltd Competitors by Total Liabilities

The table below lists competitors of Redhill Biopharma Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Matinas BioPharma Holdings Inc NYSE MKT:MTNB	USA	$2.85 Million
Nordic Asia Investment Group 1987 AB Series B ST:NAIG-B	Sweden	Skr15.54 Million
Riedel Resources Ltd AU:RIE	Australia	AU$712.75K
BGT Corporation Public Company Limited BK:BGT	Thailand	฿308.90 Million
Falmaco Nonwoven Industri PT Tbk JK:FLMC	Indonesia	Rp33.14 Billion
Aquaporin AS CO:AQP	Denmark	Dkr101.12 Million
Whitehawk Ltd AU:WHK	Australia	AU$344.64K
Spartoo SAS PA:ALSPT	France	€50.96 Million

Liability Composition Analysis (2010–2025)

This chart breaks down Redhill Biopharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Redhill Biopharma Ltd (RDHL) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.34	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	4.94	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.83	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Redhill Biopharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Redhill Biopharma Ltd (2010–2025)

The table below shows the annual total liabilities of Redhill Biopharma Ltd from 2010 to 2025.

Year	Total Liabilities	Change
2025-12-31	$21.08 Million	-7.26%
2024-12-31	$22.73 Million	+8.33%
2023-12-31	$20.98 Million	-89.88%
2022-12-31	$207.27 Million	+20.29%
2021-12-31	$172.31 Million	+3.57%
2020-12-31	$166.38 Million	+1080.23%
2019-12-31	$14.10 Million	+25.59%
2018-12-31	$11.22 Million	-8.58%
2017-12-31	$12.28 Million	+6.66%
2016-12-31	$11.51 Million	+70.51%
2015-12-31	$6.75 Million	+75.58%
2014-12-31	$3.85 Million	+59.21%
2013-12-31	$2.42 Million	+124.03%
2012-12-31	$1.08 Million	-22.94%
2011-12-31	$1.40 Million	-88.44%
2010-12-31	$12.10 Million	--

About Redhill Biopharma Ltd

NASDAQ:RDHL USA Drug Manufacturers - Specialty & Generic

Market Cap

$4.08 Million

Market Cap Rank

#28957 Global

#5862 in USA

Share Price

$0.79

Change (1 day)

-0.76%

52-Week Range

$0.74 - $2.52

All Time High

$16290.00